Cerenome vs Ocugen
Cerenome reported revenue of $5 million in fiscal 2025, 1.2 times Ocugen's $4 million in fiscal 2025. Cerenome's revenue fell 10.5% in its latest year, and Ocugen's grew 8.8%. Cerenome had an operating margin of -293.5%, against -1425.7% at Ocugen. Free cash flow was −$21 million at Cerenome and −$57 million at Ocugen.
Side by side
| Cerenome | Ocugen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $5M | $4M |
| Revenue growth | −10.5% | 8.8% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −293.5% | −1,425.7% |
| Net margin | −429.4% | −1,537.4% |
| Free cash flow | −$21M | −$57M |
| Free cash flow margin | −399.8% | −1,295.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 910.4% | — |
| Last close | $0.70 | $0.73 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $25,830, sold $589,110 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CerenomeOcugen
Operating margin
Percent of revenue
CerenomeOcugen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CerenomeOcugen